Quetiapine: A Review of its Use in the Management of Bipolar Depression
CNS Drugs,  Clinical Article

Sanford M et al. – Quetiapine and quetiapine extended–release are valuable additions to the first–line treatments for bipolar depression.

Methods
  • The efficacy and tolerability of quetiapine was evaluated in five 8-week, randomized, double-blind, placebo-controlled, multicentre or multinational trials in patients with a major depressive episode (MDE) associated with bipolar disorder.
  • Across trials, monotherapy with oral quetiapine 300 or 600 mg/day (or quetiapine XR 300 mg/day) produced significantly greater improvements than placebo in depressive symptoms (primary endpoint), according to the change in the Montgomery-Asberg Depression Rating Scale total score.
  • In general, quetiapine and quetiapine XR were also associated with significantly higher MDE response and remission rates than placebo.
  • Across trials, quetiapine and quetiapine XR produced significantly greater improvements in global severity of illness scores than placebo, according to changes in the Clinical Global Impressions scale score.
  • There were no differences in treatment outcomes between quetiapine 300 mg/day and 600 mg/day dosage groups.

Results
  • Patients with bipolar depression who responded to quetiapine during two 8-week acute treatment trials also benefited from continuing quetiapine therapy for up to 52 weeks.
  • Compared with quetiapine responders randomized to placebo, quetiapine responders who continued quetiapine 300 or 600 mg/day had a significantly reduced risk of recurrence of any mood events and of depression mood events, but not of hypomanic/manic events.
  • In a randomized, double-blind, placebo-controlled trial, quetiapine maintenance therapy for up to 104 weeks was more efficacious than placebo or lithium in prolonging the time to recurrence of any mood event (primary endpoint).
  • Patients in this trial had bipolar I disorder with mania, depression or a mixed episode as the index episode, and the trial included only patients who were responsive to acute phase quetiapine, which may have introduced a positive bias in favour of quetiapine over lithium during maintenance therapy.
  • Quetiapine 300 or 600 mg/day and quetiapine XR 300 mg/day was generally well tolerated in patients with bipolar depression, with most treatment-emergent adverse events being of mild to moderate severity.
  • The most frequent adverse events occurring during the acute treatment phase were dry mouth, sedation, somnolence, dizziness (quetiapine and quetiapine XR), constipation (quetiapine) and increased appetite (quetiapine XR).
  • Extrapyramidal symptoms (EPS) occurred across quetiapine and placebo groups, but there were no significant differences between quetiapine and placebo recipients on objective measures of EPS and akathisia.
  • In some trials, quetiapine recipients experienced significantly greater weight gain than placebo recipients.
  • Across trials, some quetiapine recipients had clinically relevant increases in blood glucose or lipid parameters, although these also occurred in patients from other treatment groups.
  • The clinical significance of these changes is uncertain.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...

Your Unread Messages in Family Medicine

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Family Medicine Articles

1 Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau) World Journal of Urology, November 3, 2014    Clinical Article

2 Impact of the 2012 United States preventive services task force statement on prostate-specific antigen screening: Analysis of urologic and primary care practices Urology, November 17, 2014    Clinical Article

3 Dairy products, calcium, and prostate cancer risk: A systematic review and meta-analysis of cohort studies American Journal of Clinical Nutrition, November 26, 2014    Clinical Article

4 Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective Urologic Oncology: Seminars and Original Investigations, November 10, 2014    Clinical Article

5 Role of ultrasensitive prostate-specific antigen in the follow-up of prostate cancer after radical prostatectomy Urologic Oncology: Seminars and Original Investigations, November 24, 2014    Clinical Article

6 Folate, vitamin B-6, and vitamin B-12 intake and mild cognitive impairment and probable dementia in the Women’s Health Initiative Memory Study Journal of the Academy of Nutrition and Dietetics, November 12, 2014    Clinical Article

7 Association of fat density with subclinical atherosclerosis Full Text Journal of the American Heart Association, September 19, 2014    Free full text

8 Acupuncture and immune function in chronic prostatitis/chronic pelvic pain syndrome: a randomized, controlled study Complementary Therapies in Medicine, October 31, 2014    Clinical Article

9 Rapid and durable protection against Ebola virus with new vaccine regimens Full Text National Institute of Allergy and Infectious Disease - News, September 9, 2014    Free full text

10 Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride The Journal of Sexual Medicine, November 7, 2014    Clinical Article

11 An European multicenter randomized noninferiority trial comparing 180-W greenlight-XPS laser vaporization and transurethral resection of the prostate for the treatment of benign prostatic obstruction: 12-months results of the goliath-study The Journal of Urology, November 4, 2014    Clinical Article

12 State-of-the-art treatment of hypertension: Established and new drugs Full Text European Heart Journal, November 14, 2013    Free full text    Clinical Article

13 A comparison of different oral therapies versus no treatment for erectile dysfunction in 196 radical nerve-sparing radical prostatectomy patients International Journal of Impotence Research: The Journal of Sexual Medicine, August 12, 2014    Clinical Article

14 Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening The Journal of Urology, November 11, 2014    Clinical Article

15 Effect of surgical margin status after radical prostatectomy on health-related quality of life and illness perception in patients with prostate cancer Urologic Oncology: Seminars and Original Investigations, November 25, 2014    Clinical Article

16 Carbohydrate intake, glycemic index and prostate cancer risk The Prostate, November 26, 2014    Clinical Article

17 Depression, anxiety, antidepressant use, and cardiovascular disease among Hispanic men and women of different national backgrounds: results from the Hispanic Community Health Study/Study of Latinos Annals of Epidemiology , November 14, 2014    Clinical Article

18 Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials JAMA Psychiatry, October 21, 2014    Evidence Based Medicine    Clinical Article

19 A clinical randomized controlled trial of music therapy and progressive muscle relaxation training in female breast cancer patients after radical mastectomy: Results on depression, anxiety and length of hospital stay European Journal of Oncology Nursing , November 5, 2014    Clinical Article

20 Comparison of cognitive behavioral therapy and supportive psychotherapy for the treatment of depression following traumatic brain injury: a randomized controlled trial Journal of Head Trauma Rehabilitation, November 20, 2014    Clinical Article

Indexed Journals in Family Medicine: American Family Physician, Archives of Family Med, Annals of Family Medmore